Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 24, 2017 ) This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/mantle-cell-lymphoma-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172452/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
AbbVie Inc.
Accentia Biopharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Advancell
Affimed Therapeutics AG
Amgen Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Bayer AG
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc
ImmunoGen, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Nordic Nanovector AS
Novartis AG
Onconova Therapeutics, Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Stemline Therapeutics, Inc.
Teva Pharmaceutical Industries Limited
TG Therapeutics, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172452/discount
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H1 2015 15
Number of Products under Development for Mantle Cell Lymphoma-Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Mantle Cell Lymphoma-Pipeline by AbbVie Inc., H1 2015 30
Mantle Cell Lymphoma-Pipeline by Accentia Biopharmaceuticals, Inc., H1 2015 31
Mantle Cell Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32
Mantle Cell Lymphoma-Pipeline by Advancell, H1 2015 33
Mantle Cell Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 34
Mantle Cell Lymphoma-Pipeline by Amgen Inc., H1 2015 35
Mantle Cell Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 36
Mantle Cell Lymphoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37
Mantle Cell Lymphoma-Pipeline by Bayer AG, H1 2015 38
Mantle Cell Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 39
Mantle Cell Lymphoma-Pipeline by Celgene Corporation, H1 2015 40
Mantle Cell Lymphoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 41
Mantle Cell Lymphoma-Pipeline by Eisai Co., Ltd., H1 2015 42
Mantle Cell Lymphoma-Pipeline by Eli Lilly and Company, H1 2015 43
Mantle Cell Lymphoma-Pipeline by EpiZyme, Inc., H1 2015 44
Mantle Cell Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 45
Mantle Cell Lymphoma-Pipeline by GlaxoSmithKline plc, H1 2015 46
Mantle Cell Lymphoma-Pipeline by ImmunoGen, Inc., H1 2015 47
Mantle Cell Lymphoma-Pipeline by Incyte Corporation, H1 2015 48
Mantle Cell Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 49
Mantle Cell Lymphoma-Pipeline by Johnson & Johnson, H1 2015 50
Mantle Cell Lymphoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51
Mantle Cell Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 52
Mantle Cell Lymphoma-Pipeline by MedImmune, LLC, H1 2015 53
Mantle Cell Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 54
Mantle Cell Lymphoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55
Mantle Cell Lymphoma-Pipeline by MorphoSys AG, H1 2015 56
Mantle Cell Lymphoma-Pipeline by Nordic Nanovector AS, H1 2015 57
Mantle Cell Lymphoma-Pipeline by Novartis AG, H1 2015 58
Mantle Cell Lymphoma-Pipeline by Onconova Therapeutics, Inc., H1 2015 59
Mantle Cell Lymphoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 60
Mantle Cell Lymphoma-Pipeline by Pfizer Inc., H1 2015 61
Mantle Cell Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 62
Mantle Cell Lymphoma-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 63
Mantle Cell Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 64
Mantle Cell Lymphoma-Pipeline by Sevion Therapeutics, Inc., H1 2015 65
Mantle Cell Lymphoma-Pipeline by Stemline Therapeutics, Inc., H1 2015 66
Mantle Cell Lymphoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 67
Mantle Cell Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 68
Assessment by Monotherapy Products, H1 2015 69
Assessment by Combination Products, H1 2015 70
Number of Products by Stage and Target, H1 2015 72
Number of Products by Stage and Mechanism of Action, H1 2015 75
Number of Products by Stage and Route of Administration, H1 2015 78
Number of Products by Stage and Molecule Type, H1 2015 80
Mantle Cell Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 214
Mantle Cell Lymphoma-Dormant Projects, H1 2015 319
Mantle Cell Lymphoma-Dormant Projects (Contd..1), H1 2015 320
Mantle Cell Lymphoma-Discontinued Products, H1 2015 321
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172452/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|